United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Plato Investment Management Ltd

Plato Investment Management Ltd boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 7.1% during the second quarter, HoldingsChannel.com reports. The firm owned 4,008 shares of the biotechnology company’s stock after purchasing an additional 264 shares during the period. Plato Investment Management Ltd’s holdings in United Therapeutics were worth $1,277,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. ClariVest Asset Management LLC raised its stake in shares of United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares during the period. Access Investment Management LLC lifted its holdings in United Therapeutics by 0.8% during the second quarter. Access Investment Management LLC now owns 7,265 shares of the biotechnology company’s stock valued at $2,314,000 after purchasing an additional 55 shares in the last quarter. MBM Wealth Consultants LLC increased its stake in shares of United Therapeutics by 2.7% during the first quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock worth $515,000 after purchasing an additional 59 shares in the last quarter. Fifth Third Bancorp increased its stake in shares of United Therapeutics by 13.2% during the second quarter. Fifth Third Bancorp now owns 585 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 68 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in United Therapeutics by 3.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 2,666 shares of the biotechnology company’s stock valued at $849,000 after buying an additional 81 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

United Therapeutics stock opened at $339.12 on Monday. The firm has a 50 day simple moving average of $336.73 and a 200-day simple moving average of $287.95. The stock has a market cap of $15.09 billion, a price-to-earnings ratio of 16.03, a price-to-earnings-growth ratio of 1.23 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $366.08.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The business had revenue of $714.90 million during the quarter, compared to analyst estimates of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company’s revenue was up 19.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.24 earnings per share. On average, analysts expect that United Therapeutics Co. will post 24.86 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Wells Fargo & Company boosted their price objective on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. JPMorgan Chase & Co. raised their price objective on United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a report on Tuesday, May 21st. HC Wainwright reaffirmed a “buy” rating and set a $400.00 target price on shares of United Therapeutics in a report on Thursday, August 1st. TD Cowen raised their price target on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Finally, StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $350.36.

Insider Transactions at United Therapeutics

In related news, CFO James Edgemond sold 7,802 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $345.41, for a total value of $2,694,888.82. Following the sale, the chief financial officer now directly owns 3,210 shares in the company, valued at approximately $1,108,766.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other United Therapeutics news, CFO James Edgemond sold 7,802 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $345.41, for a total value of $2,694,888.82. Following the sale, the chief financial officer now owns 3,210 shares of the company’s stock, valued at $1,108,766.10. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 25,000 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total value of $8,084,500.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $833,350.26. The disclosure for this sale can be found here. In the last ninety days, insiders sold 114,522 shares of company stock worth $37,671,474. 12.50% of the stock is currently owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.